The company lists dozens of job openings in Austin, including engineer and administration roles.
Dubbed a patient-in-residence at Bakar Bio Labs, where he was embedded earlier this year with gene therapy startup NV ...
Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodiesComplete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results